FundedIQ
Biotechnology

BridgeBio Pharma: Funding, Investors & Team (Sep 2026)

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

bridgebio.com LinkedIn Palo Alto, United States 251-500 employees
Biotechnology Health Care Life Science Medical Pharmaceutical
Total raised
$1.3B
Rounds
2
Latest
Undisclosed round
Feb 2025

BridgeBio Pharma has raised $1.3B across 2 funding rounds on record, the most recent an undisclosed round of $500M announced in Feb 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

BridgeBio Pharma Company Profile and Key Stats

Total funding raised
$1.3B
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Undisclosed round
$500M in Feb 2025
Employees
251-500
reported band
Headquarters
Palo Alto, United States

Latest funding round on record: Feb 2025.

BridgeBio Pharma Funding Rounds

Date
Round
Amount
Undisclosed round
$500M
Post-IPO Debt
$750M

BridgeBio Pharma raised $750M in a Post-IPO Debt announced in Nov 2021.

3.3 years later, an undisclosed round of $500M was announced in Feb 2025.

BridgeBio Pharma Founders and Leadership Team

Name
Role
Contact
Neil Kumar
Founder
Locked

Contact details for the BridgeBio Pharma team: 1 of 1 has an email address on file.

Start 14-day free trial →

BridgeBio Pharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M

BridgeBio Pharma's latest round of $500M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like BridgeBio Pharma in Biotechnology and Palo Alto

Companies Similar to BridgeBio Pharma

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

BridgeBio Pharma Funding FAQs

What does BridgeBio Pharma do?

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

How much funding has BridgeBio Pharma raised?

BridgeBio Pharma has raised $1.3B across 2 rounds on record. The most recent is an undisclosed round of $500M announced in Feb 2025.

When did BridgeBio Pharma last raise funding?

BridgeBio Pharma's most recent funding round on record is an undisclosed round of $500M, announced in Feb 2025.

Who founded BridgeBio Pharma?

FundedIQ lists Neil Kumar (Founder) at BridgeBio Pharma.

Where is BridgeBio Pharma headquartered?

BridgeBio Pharma is based in Palo Alto, California, United States.

How many employees does BridgeBio Pharma have?

BridgeBio Pharma is in the 251-500 employee band.

How does BridgeBio Pharma's funding compare to other Biotechnology startups?

BridgeBio Pharma's latest round of $500M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's BridgeBio Pharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BridgeBio Pharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.